Sequent Medical Announces Closing of US$15.6 Million Venture Capital Financing

ALISO VIEJO, California, May 13, 2010 - Sequent Medical, Inc. announced today that it has closed a US$15.6
million Series B venture capital financing. The financing was led by Domain
Associates, joined by existing investors Versant Ventures and US Venture
Partners. Nimesh Shah of Domain will join Sequent's Board of Directors.

"We are privileged to have such a high caliber group of investors, and
would like to welcome both Domain Associates as an investor in Sequent and
Nimesh Shah as a Board member," said Tom Wilder, who joined in February 2010
as President and Chief Executive Officer. "We will utilize these funds to
continue our development programs, including the introduction of our initial
WEB(TM) product line." The WEB(TM) aneurysm embolization system provides a
new treatment alternative for cerebral aneurysms, especially those prone to a
high rate of recurrence and treatment.

About Sequent Medical, Inc.

Sequent Medical, Inc. (www.sequentmedical.com) was founded by Bob
Rosenbluth, Ph.D. and Brian Cox, with Versant Ventures and US Venture
Partners as founding investors. Sequent is dedicated to the development of
innovative devices to advance the endovascular treatment of neurovascular
disease conditions. Rosenbluth and Cox previously founded MicroVention, Inc.,
now known as MicroVention Terumo. Sequent has developed proprietary fine wire
fabrication technology to create a low porosity device that is deployed
within the aneurysm to facilitate occlusion and healing. The market for
endovascular treatment of cerebral aneurysms continues to grow rapidly, as
improvements in technology, such as the WEB, allow an increasing number of
aneurysms to be treated non-surgically.

Thomas C. Wilder, III, President and Chief Executive Officer of Sequent Medical, Inc., +1-949-830-9600